Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients.


Journal

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 17 12 2020
revised: 15 07 2021
accepted: 08 08 2021
pubmed: 23 8 2021
medline: 21 12 2021
entrez: 22 8 2021
Statut: ppublish

Résumé

SARS-CoV-2 attaches to the angiotensin-converting enzyme 2 (ACE-2) receptor on human cells. The virus causes hypercytokinemia, capillary leak, pulmonary edema, acute respiratory distress syndrome, acute cardiac injury, and leads to death. Mesenchymal stem cells (MSCs) are ACE-2 negative cells; therefore, can escape from SARS-CoV-2. MSCs prevent hypercytokinemia and help the resolution of the pulmonary edema and other damages occurred during the course of COVID-19. In addition, MSCs enhance the regeneration of the lung and other tissues affected by SARS-CoV-2. The case series reported beneficial effect of MSCs in COVID-19 treatment. However, there are some concerns about the safety of MSCs, particularly referring to the increased risk of disseminated intravascular coagulation, and thromboembolism due to the expression of TF/CD142. Prospective, randomized, large scale studies are needed to reveal the optimum dose, administration way, time, efficacy, and safety of MSCs in the COVID-19 treatment.

Identifiants

pubmed: 34419356
pii: S1473-0502(21)00229-9
doi: 10.1016/j.transci.2021.103237
pmc: PMC8372452
pii:
doi:

Substances chimiques

Thromboplastin 9035-58-9
ACE protein, human EC 3.4.15.1
Peptidyl-Dipeptidase A EC 3.4.15.1

Types de publication

Journal Article Review

Langues

eng

Pagination

103237

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Blood. 2009 Jun 25;113(26):6576-83
pubmed: 19398717
Mediterr J Hematol Infect Dis. 2019 Jan 01;11(1):e2019006
pubmed: 30671212
Respiration. 2013;85(4):267-78
pubmed: 23428562
Int J Hematol. 2004 Feb;79(2):103-8
pubmed: 15005335
J Immunol Res. 2014;2014:657625
pubmed: 24818168
J Oncol Pharm Pract. 2020 Oct;26(7):1676-1682
pubmed: 32854573
Cell Stem Cell. 2013 Oct 3;13(4):392-402
pubmed: 24094322
Hum Immunol. 2020 Dec;81(12):697-701
pubmed: 33046268
Stem Cell Res Ther. 2020 Aug 18;11(1):361
pubmed: 32811531
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Stem Cells Int. 2019 May 2;2019:4236973
pubmed: 31191672
Trends Mol Med. 2019 Feb;25(2):149-163
pubmed: 30711482
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670
pubmed: 32196083
Signal Transduct Target Ther. 2020 Aug 27;5(1):172
pubmed: 32855385
J Assist Reprod Genet. 2007 Jul;24(7):288-95
pubmed: 17629722
Lancet Haematol. 2016 Jan;3(1):e45-52
pubmed: 26765648
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Biomed Pharmacother. 2018 Jun;102:333-343
pubmed: 29571018
Cell Physiol Biochem. 2016;39(4):1553-60
pubmed: 27614987
Sci Transl Med. 2019 Feb 20;11(480):
pubmed: 30787168
Cytotherapy. 2004;6(6):543-53
pubmed: 15770794
QJM. 2016 May;109(5):331-6
pubmed: 26819296
Clin Transl Immunology. 2020 May 10;9(5):e1128
pubmed: 32399213
Expert Rev Respir Med. 2020 Jan;14(1):31-39
pubmed: 31608724
Medicine (Baltimore). 2020 Jul 31;99(31):e21429
pubmed: 32756149
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
PLoS Biol. 2006 Jan;4(1):e9
pubmed: 16366734
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Stem Cells Transl Med. 2019 Aug;8(8):785-796
pubmed: 31033196
Blood. 2006 Jan 1;107(1):367-72
pubmed: 16141348
Transfus Apher Sci. 2020 Oct;59(5):102940
pubmed: 32950375
Transfus Apher Sci. 2020 Oct;59(5):102941
pubmed: 32958397
Immunol Lett. 2015 Dec;168(2):140-6
pubmed: 25982165
Stem Cell Res Ther. 2014 Aug 13;5(4):97
pubmed: 25124290
Blood. 2005 Feb 15;105(4):1815-22
pubmed: 15494428
BMC Pulm Med. 2015 Jun 11;15:66
pubmed: 26059242
Turk J Med Sci. 2020 Apr 15;50(SI-1):611-619
pubmed: 32293834
Bone. 2006 Sep;39(3):513-22
pubmed: 16616713
J Med Virol. 2021 Feb;93(2):1099-1104
pubmed: 32776581
Lancet Respir Med. 2019 Feb;7(2):154-162
pubmed: 30455077
Curr Top Microbiol Immunol. 2004;280:71-109
pubmed: 14594208
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cancer Res. 2009 Jul 1;69(13):5331-9
pubmed: 19509230
Cell Tissue Bank. 2014 Dec;15(4):513-21
pubmed: 24407613
Med Drug Discov. 2020 Mar;5:100019
pubmed: 32296777
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Cell Stem Cell. 2018 Jun 01;22(6):824-833
pubmed: 29859173
Transplant Proc. 2017 Sep;49(7):1656-1658
pubmed: 28838459
Nat Med. 2012 Apr 15;18(5):759-65
pubmed: 22504485
Stem Cells. 2007 Feb;25(2):371-9
pubmed: 17038675
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
PLoS One. 2014 May 12;9(5):e96662
pubmed: 24819371
Nephrol Dial Transplant. 2012 Aug;27(8):3037-42
pubmed: 22851627
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Biochem Biophys Res Commun. 2013 Feb 8;431(2):203-9
pubmed: 23313481
Best Pract Res Clin Obstet Gynaecol. 2016 Feb;31:30-44
pubmed: 26482184
PLoS One. 2012;7(10):e47559
pubmed: 23133515
Lancet Haematol. 2020 May;7(5):e362-e363
pubmed: 32278361
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Crit Care Med. 2012 Apr;40(4):1245-53
pubmed: 22202710
Ann Hematol. 2012 Oct;91(10):1563-77
pubmed: 22696050

Auteurs

Tuğçe Nur Yiğenoğlu (TN)

University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey. Electronic address: dr.nuryigenoglu@gmail.com.

Semih Başcı (S)

University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey. Electronic address: dr.semihbasci@gmail.com.

Derya Şahin (D)

University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey. Electronic address: dr.deryasahin@hotmail.com.

Turgay Ulaş (T)

Near East University, School of Medicine, Department of Internal Medicine, Department of Hematology, Cyprus. Electronic address: turgayulas@yahoo.com.

Mehmet Sinan Dal (MS)

University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey. Electronic address: dr.sinandal@gmail.com.

Serdal Korkmaz (S)

University of Health Sciences, Kayseri Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Kayseri, Turkey. Electronic address: baranserdalkorkmaz@gmail.com.

Tuba Hacıbekiroğlu (T)

Sakarya University, School of Medicine, Department of Internal Medicine, Division of Hematology, Sakarya, Turkey. Electronic address: tubahacibekiroglu@sakarya.edu.tr.

Sinem Namdaroğlu (S)

University of Health Sciences, Bozyaka Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Izmir, Turkey. Electronic address: drsinemnamdaroglu@gmail.com.

Mehmet Ali Erkurt (MA)

Inonu University, School of Medicine, Department of Internal Medicine, Division of Hematology and Bone Marrow Transplantation Center, Malatya, Turkey. Electronic address: erkurtali@hotmail.com.

Burhan Turgut (B)

Namık Kemal University, School of Medicine, Department of Internal Medicine, Division of Hematology and Bone Marrow Transplantation Center, Tekirdağ, Turkey. Electronic address: burhanturgut@hotmail.com.

Fevzi Altuntaş (F)

University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, Ankara, Turkey; Ankara Yıldırım Beyazıt University, School of Medicine, Department of Internal Medicine, Division of Hematology, Ankara, Turkey. Electronic address: faltuntas@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH